

ORIGINAL ARTICLE

# The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States

Steven E. Lipshultz, M.D., Lynn A. Sleeper, Sc.D., Jeffrey A. Towbin, M.D., April M. Lowe, M.S., E. John Orav, Ph.D., Gerald F. Cox, M.D., Ph.D., Paul R. Lurie, M.D., Kristina L. McCoy, R.N., Melissa A. McDonald, M.P.H., Jane E. Messere, R.N., and Steven D. Colan, M.D.

## ABSTRACT

### BACKGROUND

Population-based data on the incidence of pediatric cardiomyopathy are rare because of the lack of large, prospective studies.

### METHODS

Since 1996 the Pediatric Cardiomyopathy Registry sponsored by the National Heart, Lung, and Blood Institute has collected data on all children with newly diagnosed cardiomyopathy in New England and the Central Southwest region (Texas, Oklahoma, and Arkansas) of the United States. We report on all children in these regions who received this diagnosis between 1996 and 1999.

### RESULTS

We identified 467 cases of cardiomyopathy, for an overall annual incidence of 1.13 per 100,000 children (95 percent confidence interval, 1.03 to 1.23). The incidence was significantly higher among infants younger than 1 year old than among children and adolescents who were 1 to 18 years old (8.34 vs. 0.70 per 100,000,  $P < 0.001$ ). The annual incidence of cardiomyopathy was lower among white children (upper-bound estimate, 1.06 cases per 100,000) than among black children (lower-bound estimate, 1.47 per 100,000;  $P = 0.02$ ) and higher among boys than among girls (1.32 vs. 0.92 per 100,000,  $P < 0.001$ ). The incidence also varied significantly by region: 1.44 cases per 100,000 in New England and 0.98 per 100,000 in the Central Southwest region ( $P < 0.001$ ). When categorized according to type, dilated cardiomyopathy made up 51 percent of the cases, hypertrophic cardiomyopathy 42 percent, and restrictive or other types 3 percent; 4 percent were unspecified. There was no significant difference in the incidence rates according to the year.

### CONCLUSIONS

The estimated incidence of pediatric cardiomyopathy in two large regions of the United States is 1.13 cases per 100,000 children. Most cases are identified at an early age, and the incidence varies according to sex, region, and racial or ethnic origin.

From the Division of Pediatric Cardiology, Golisano Children's Hospital at Strong and University of Rochester Medical Center, and the Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, N.Y. (S.E.L., K.L.M., M.A.M.); the Department of Cardiology (S.E.L., J.E.M., S.D.C.) and the Division of Genetics (G.F.C.), Children's Hospital, Boston; the Department of Pediatrics, Harvard Medical School, Boston (S.E.L., G.F.C., S.D.C.); New England Research Institutes, Watertown, Mass. (L.A.S., A.M.L.); the Department of Pediatric (Cardiology), Molecular and Human Genetics, and Cardiovascular Sciences, Texas Children's Hospital and Baylor College of Medicine, Houston (J.A.T.); the Department of Medicine, Brigham and Women's Hospital, Boston (E.J.O.); Genzyme Corporation, Cambridge, Mass. (G.F.C.); and the Department of Pediatrics, Albany Medical College, Albany, N.Y. (P.R.L.). Address reprint requests to Dr. Lipshultz at the Division of Pediatric Cardiology, University of Rochester Medical Center, 601 Elmwood Ave., Box 631, Rochester, NY 14642, or at [steve\\_lipshultz@urmc.rochester.edu](mailto:steve_lipshultz@urmc.rochester.edu).

N Engl J Med 2003;348:1647-55.

Copyright © 2003 Massachusetts Medical Society.

**C**ARDIOMYOPATHY IS A VERY SERIOUS disorder in children, and nearly 40 percent of children who present with symptomatic cardiomyopathy receive a heart transplant or die within the first two years.<sup>1</sup> The time to transplantation or death for children with cardiomyopathy has not improved during the past 35 years, and the outcomes in the most economically advanced nations are no better than those in developing nations.<sup>2-4</sup>

The cardiomyopathies have an associated cost of nearly \$200 million per year in adults and children in the United States alone.<sup>5,6</sup> The percentage of children with cardiomyopathy who receive a heart transplant has not declined over the past 10 years, and cardiomyopathy remains the leading cause of transplantation in children over one year of age.<sup>7</sup> The true incidence of pediatric cardiomyopathy is unclear. In a retrospective study of idiopathic dilated cardiomyopathy in children in Finland, the estimated incidence was 0.65 case per 100,000.<sup>8,9</sup> Results of a 10-year study in Australia, which appear elsewhere in this issue of the *Journal*, suggest an incidence of pediatric cardiomyopathy of 1.24 cases per 100,000 children, with an annual incidence of dilated cardiomyopathy of 0.73 per 100,000 children and an incidence of hypertrophic cardiomyopathy of 0.32 per 100,000 children.<sup>10</sup>

The assessment of the incidence of pediatric cardiomyopathy in the United States has been confounded by socioeconomic, geographic, racial, and ethnic diversity. Information is based on small retrospective studies, many of which were done before the advent of echocardiography.

This study presents results from a registry begun in 1996 that prospectively attempted to identify all cases of pediatric cardiomyopathy in two geographically distinct regions of the United States. Our goal was to determine the annual incidence of pediatric cardiomyopathy in these regions and to determine whether the incidence varies according to region, racial or ethnic group, time, sex, age, and type of cardiomyopathy.

---

## METHODS

---

### STUDY DESIGN

The design of the Pediatric Cardiomyopathy Registry, which is sponsored by the National Heart, Lung, and Blood Institute, has been described elsewhere.<sup>11</sup> All patients presenting to pediatric cardiologists in 18 centers in New England and 20 centers in the Central Southwest (in Texas, Oklahoma,

and Arkansas) are prospectively identified and entered into the registry data base. A survey of pediatric practices in these regions has indicated that the clinical sites identified nearly all diagnosed cases, with the possible exception of one center in Oklahoma. Patients at this site are sometimes referred to Texas and registered there, but we estimate that two to five cases per year are missed. Patients who lived in the New England or Central Southwest region but who received care outside that region were still included.

This analysis is based on the prospective component of the Pediatric Cardiomyopathy Registry data base, consisting of patients who have received a diagnosis of cardiomyopathy since January 1, 1996. The protocol was approved by the institutional review board or ethics committee at every participating site.

### ELIGIBILITY CRITERIA

To be eligible for this analysis, a patient was required to live in one of the two regions, to be younger than 18 years of age at diagnosis, and to have one of the following: echocardiographic evidence of cardiomyopathy, including at least two left ventricular measurements (fractional shortening, posterior-wall thickness, or end-diastolic dimension or volume) exceeding 2 SD for age (fractional shortening) or for body-surface area (all other measurements)<sup>12</sup>; an echocardiographic pattern of cardiomyopathy, with localized ventricular hypertrophy or restrictive cardiomyopathy or a contracted form of endocardial fibroelastosis; a pathological diagnosis of cardiomyopathy at autopsy or endomyocardial biopsy; or other clinical evidence of cardiomyopathy provided by the cardiologist. There were 14 clinical exclusion criteria, including a congenital heart defect not associated with a malformation syndrome, endocrine disease known to cause myocardial damage, chronic arrhythmia, pulmonary parenchymal or vascular disease, immunologic disease, chemotherapy-associated cardiotoxicity, and drug use known to cause hypertrophy.<sup>11</sup>

### DATA COLLECTION

Data for the Pediatric Cardiomyopathy Registry are collected through on-site abstraction of records by a trained outreach team or research staff at the participating clinical site. This report is based on data collected at enrollment (defined as the month of diagnosis). Enrollment postcards and data-collection forms with patient-identification labels generated

by computer at the data-coordinating center are sent to each site. The study coordinator, in conjunction with the cardiologists at each site, is responsible for identifying all local cases of pediatric cardiomyopathy.

The completeness of the data base has been assessed in multiple ways. After the study period included in this report, we conducted a survey of all 239 adult cardiology practices in Rhode Island and Arkansas. The cardiologists were asked whether they cared for any children with cardiomyopathy who were not also under the care of a pediatric cardiologist. None of the 154 respondents reported caring for such a patient. In 1998, at a single large New England institution, we electronically scanned all echocardiograms obtained during the year and identified more than 600 children who appeared to meet the inclusion criteria for our study. However, all these children were either already registered in our data base or met exclusion criteria. In the same year, three institutions participated in a review of *International Classification of Diseases, 9th Revision (ICD-9)* discharge codes in hopes of identifying children with cardiomyopathy who had not already been included in our registry with the use of our conventional methods. The reviews uncovered no new cases.

**STATISTICAL ANALYSIS**

Numerators for the reported incidence rates are based on patients who received a diagnosis of cardiomyopathy between 1996 and 1999. Population estimates (incidence-rate denominators) are taken from the 1990 U.S. Census, with an in- and out-migration algorithm applied to obtain year-specific population estimates.<sup>13</sup> Three racial and ethnic categories are presented: white, black, and Hispanic. For these categories, the Pediatric Cardiomyopathy Registry data consisted of a single question with a choice of white, black, or Hispanic. However, the Census cross-tabulates Hispanic status according to racial category. Therefore, we calculated both lower-bound and upper-bound estimates of race-specific incidence rates. The lower-bound estimate includes all white Hispanics and black Hispanics in the white and black population counts, respectively, and the upper bound includes none of the white Hispanics and black Hispanics in the white and black population counts, respectively. The lower-bound estimate for the Hispanic rate includes all Hispanics of any race (white, black, or other race) in the population count, and the upper-bound estimate

for the Hispanic rate includes only Hispanics with a racial background not classified as white or black in the population count. The latter estimate has a high variance and instability because of the very small estimated Hispanic population, and thus, we conducted statistical comparisons only between white and black patients. This comparison was conducted in the most conservative fashion — that is, the upper-bound incidence for whites was compared with the lower-bound incidence for blacks.

Because of the rarity of observed cases, incidence rates in various subgroups (region, year, sex, racial

**Table 1. Base-Line Characteristics of the 467 Children with Cardiomyopathy Diagnosed in 1996, 1997, 1998, and 1999.**

Characteristic	No. of Patients (%)
Year of diagnosis	
1996	132 (28)
1997	121 (26)
1998	114 (24)
1999	100 (21)
Region	
New England	186 (40)
Central Southwest	281 (60)
Sex	
Male	281 (60)
Female	186 (40)
Racial or ethnic group	
White	270 (58)
Black	73 (16)
Hispanic	108 (23)
Other	16 (3)
Age	
<1 yr	193 (41)
1 to <6 yr	71 (15)
6 to <12 yr	66 (14)
12 to <18 yr	137 (29)
Type of cardiomyopathy	
Hypertrophic*	196 (42)
Dilated	239 (51)
Other†	15 (3)
Unspecified	17 (4)

\* Twelve of the 196 cases of hypertrophic cardiomyopathy were the mixed type. Hypertrophic cardiomyopathy was defined by the presence of at least one of the following criteria: a left ventricular wall that was more than 2 SD above the normal thickness, an echocardiographic pattern consistent with the presence of hypertrophic cardiomyopathy, or a pathological diagnosis of hypertrophic cardiomyopathy.

† “Other” includes restrictive and other identified types of cardiomyopathy.

**Table 2. Annual Incidence of Pediatric Cardiomyopathy in New England and the Central Southwest on the Basis of Cases Diagnosed in 1996, 1997, 1998, and 1999.\***

Variable	Both Regions (N=467)	New England (N=186)	Central Southwest (N=281)	P Value†
<i>incidence/100,000 children (95% CI)</i>				
Overall incidence	1.13 (1.03–1.23)	1.44	0.98	<0.001
Year‡				
1996	1.29 (1.08–1.53)	1.78	1.07	0.005
1997	1.17 (0.97–1.40)	1.43	1.05	0.12
1998	1.09 (0.90–1.31)	1.30	1.00	0.19
1999	0.95 (0.77–1.15)	1.25	0.81	0.04
Sex§				
Male	1.32 (1.17–1.49)	1.80	1.11	<0.001
Female	0.92 (0.79–1.06)	1.06	0.85	0.15
Racial or ethnic group¶				
White				
Lower bound	0.77	1.25	0.55	<0.001
Upper bound	1.06	1.35	0.85	<0.001
Black				
Lower bound	1.47	1.52	1.46	0.89
Upper bound	1.60	1.85	1.54	0.55
Hispanic				
Lower bound	1.09	1.90	0.99	—
Upper bound	59.42	70.76	57.20	—
Age§				
<1 yr	8.34 (7.21–9.61)	9.72	7.78	0.15
1 to <6 yr	0.62 (0.48–0.78)	0.81	0.53	0.09
6 to <12 yr	0.47 (0.37–0.60)	0.60	0.42	0.15
12 to <18 yr	1.00 (0.84–1.18)	1.55	0.75	<0.001
Type of cardiomyopathy				
Hypertrophic	0.47 (0.41–0.54)	0.61	0.41	0.007
Dilated	0.58 (0.51–0.65)	0.74	0.50	0.003
Other	0.04 (0.02–0.06)	0.05	0.03	0.58

\* CI denotes confidence interval.

† P values are for the comparison of the New England region with the Central Southwest region. There were no significant interactions between the children's characteristics and region.

‡ P=0.13 for the overall comparison.

§ P<0.001 for the overall comparison.

¶ Because of an inconsistency in the definitions of racial and ethnic groups between the U.S. Census data and our registry, both an upper-bound estimate and a lower-bound estimate of the incidence rate are given for white, black, and Hispanic children. P=0.02 for the conservative comparison between the upper-bound estimate for whites and the lower-bound estimate for blacks.

|| "Other" includes restrictive and other identified types of cardiomyopathy. Seventeen children with an unspecified type of cardiomyopathy were excluded from the analysis.

or ethnic group, and age) were compared with the use of two-sided Fisher exact tests and exact 95 percent confidence intervals. Comparisons according to the type of cardiomyopathy were conducted with the use of Poisson regression because the at-risk populations were not independent. Tests of inter-

action were conducted with the use of logistic regression and Poisson regression to assess the significance of subgroup findings. All reported P values are based on two-sided tests.

## RESULTS

Table 1 shows the base-line characteristics of the 467 children with cardiomyopathy who were enrolled between 1996 and 1999 in New England (40 percent) and the Central Southwest (60 percent) of the United States. Sixty percent were boys, and 58 percent were white. Almost half (41 percent) received a diagnosis of cardiomyopathy within the first 12 months of life. Dilated cardiomyopathy was the most common type, accounting for 51 percent of cases.

The overall annual incidence of cardiomyopathy (Table 2) was 1.13 cases per 100,000 children (95 percent confidence interval, 1.03 to 1.23 cases per 100,000). The incidence of cardiomyopathy was significantly higher in New England than in the Central Southwest (1.44 vs. 0.98 cases per 100,000, P<0.001). The directly standardized rates adjusted for sex, age, and racial or ethnic group according to the U.S. population younger than 18 years of age were 1.59 per 100,000 for New England and 0.84 per 100,000 for the Central Southwest (P<0.001). There was no significant difference in incidence among the years. Boys were more likely to receive a diagnosis of cardiomyopathy than girls, and the regional difference was more marked in boys than in girls. The incidence varied according to age, with children younger than one year of age nearly 12 times as likely to receive a diagnosis of cardiomyopathy as children who were one year of age or older (8.34 vs. 0.70 cases per 100,000). Racial or ethnic group was also significantly associated with the incidence of cardiomyopathy, with white children having the lowest incidence.

The incidence of cardiomyopathy differed depending on the type: dilated cardiomyopathy was the most common, hypertrophic cardiomyopathy was the second most common, and other types of cardiomyopathy, including restrictive and arrhythmic, were rarer (Table 1). There were no significant interactions between any of these subgroups and geographic region.

Table 3 presents incidence rates for all two-way combinations of subgroups. There was only one significant interaction, and that was between the age at diagnosis and sex (P=0.004). There was no signif-

**Table 3. Annual Incidence of Cardiomyopathy in Various Subgroups on the Basis of Cases Diagnosed in 1996, 1997, 1998 and 1999.\***

Variable	Year of Diagnosis				Sex		Age		Type	
	1996 (N=132)	1997 (N=121)	1998 (N=114)	1999 (N=100)	Male (N=281)	Female (N=186)	<1 yr (N=193)	1-18 yr (N=274)	HCM (N=196)	DCM (N=239)
Overall incidence	1.29	1.17	1.09	0.95	1.32	0.92	8.34	0.70	0.47	0.58
<i>annual incidence per 100,000 children</i>										
Year										
1996	—	—	—	—	1.64	0.92	10.72	0.74	0.65	0.61
1997	—	—	—	—	1.29	1.05	8.50	0.74	0.41	0.71
1998	—	—	—	—	1.16	1.02	8.25	0.67	0.44	0.58
1999	—	—	—	—	1.20	0.68	5.98	0.65	0.40	0.41
Sex										
Male	1.64	1.29	1.16	1.20	—	—	8.56	0.90	0.59	0.67
Female	0.92	1.05	1.02	0.68	—	—	8.12	0.49	0.35	0.48
Racial or ethnic group†										
White										
Lower bound	0.88	0.82	0.70	0.70	0.89	0.65	5.08	0.52	0.38	0.37
Upper bound	1.19	1.11	0.96	0.97	1.21	0.89	7.50	0.71	0.47	0.51
Black										
Lower bound	1.63	1.54	1.93	0.80	1.90	1.03	11.55	0.91	0.58	0.81
Upper bound	1.77	1.67	2.10	0.87	2.07	1.12	12.90	0.99	0.64	0.88
Hispanic										
Lower bound	1.41	1.19	0.95	0.84	1.19	0.99	8.55	0.55	0.38	0.62
Upper bound	78.20	65.15	51.48	45.42	65.06	53.60	561.24	29.72	20.90	33.55
Age										
<1 yr	10.72	8.50	8.25	5.98	8.56	8.12	—	—	3.20	4.58
1-18 yr	0.74	0.74	0.67	0.65	0.90	0.49	—	—	0.31	0.34
Type of cardiomyopathy										
Hypertrophic	0.65	0.41	0.44	0.40	0.59	0.35	3.20	0.31	—	—
Dilated	0.61	0.71	0.58	0.41	0.67	0.48	4.58	0.34	—	—

\* HCM denotes hypertrophic cardiomyopathy, and DCM dilated cardiomyopathy. There was a significant interaction between sex and age (P=0.004).

† Because of an inconsistency in the definitions of racial and ethnic groups between the U.S. Census data and our registry, both an upper-bound estimate and a lower-bound estimate of the incidence rate are given for white, black, and Hispanic children.

inant sex-based difference in the incidence among infants, but among children who received a diagnosis at or after the age of one year, cardiomyopathy was more common in boys.


Sixty-eight percent of the 435 cases of hypertrophic and dilated cardiomyopathy were idiopathic. Of the remaining 138 cases (Fig. 1 and Table 4), familial isolated cardiomyopathy (21 of 61 cases [34 percent]) and inborn errors of metabolism (16 of 61 cases [26 percent]) were the most common causes of hypertrophic cardiomyopathy. Neuromuscular disorders (30 of 77 cases [39 percent]) and myocarditis (21 of 77 cases [27 percent]) were the most common causes of dilated cardiomyopathy.

The median age at diagnosis was 5.9 years for hypertrophic cardiomyopathy and 1.8 years for dilated cardiomyopathy. Within one month after di-

agnosis, 58 percent of all children were given therapy for congestive heart failure, with higher usage among children with dilated cardiomyopathy than among those with hypertrophic cardiomyopathy (83 percent vs. 28 percent). The mortality rate two years after diagnosis was similar in the two groups: 12.7 percent in the group with hypertrophic cardiomyopathy and 13.6 percent in the group with dilated cardiomyopathy. The respective rates of heart transplantation two years after diagnosis were 0.8 percent and 12.7 percent.

#### DISCUSSION

We determined the incidence of pediatric cardiomyopathy in two regions of the United States and found that the incidence was higher in New England than



in the Central Southwest, among boys than among girls, and among black and Hispanic children than among white children. Cardiomyopathy was much more likely to occur during the first year of life than at other ages during childhood. Dilated cardiomyopathy was more common than hypertrophic or restrictive cardiomyopathy. There was no significant difference in the frequency of the diagnosis according to the year.

Our prospective incidence rates are higher than those reported in the retrospective Finnish study, but the Finnish rates were based on idiopathic cases.<sup>8</sup> A preliminary review of the retrospective cohort in the Pediatric Cardiomyopathy Registry showed that 69 percent of the patients had idiopathic cardiomyopathy and 31 percent had a known cause of cardiomyopathy,<sup>14</sup> suggesting that because the Finnish data were restricted to children with idiopathic cardiomyopathy, the overall annual incidence of cardiomyopathy may have been underestimated by 45 percent. Among adults, the incidence of di-

lated cardiomyopathy is higher than the incidence we found (2.4 to 8.0 per 100,000, as compared with 0.58 per 100,000), and half of adults with dilated cardiomyopathy have heart failure from ischemia.<sup>15</sup>

We found regional differences in the incidence of cardiomyopathy, even after adjustment for age, racial or ethnic group, and sex. We have no explanation for these differences in incidence. In the two regions studied, the rates tended to decrease from 1996 to 1999, but our prospective data indicate that the incidence was higher in 2000 (127 cases) than it was in 1998 (114 cases) and 1999 (100 cases), negating the downward trend over time.

The differences in incidence between boys and girls in our study, primarily among children who received a diagnosis after infancy, and the significant interaction between age and sex, were consistent with the male predominance and age-related expression of X-linked cardiomyopathies related to neuromuscular diseases. Sex-related differences in children with other types of heart disease have been

observed.<sup>3,16-18</sup> However, previous single-center studies led to the conclusion that the incidence of cardiomyopathy was similar in the two sexes.<sup>19-25</sup>

We found higher rates of cardiomyopathy in black and Hispanic children than in white children. Studies of dilated cardiomyopathy in adults have also found higher rates in blacks than in whites but were unable to determine whether the differences were due to genetic or environmental factors.<sup>26</sup> Racial and ethnic differences have been found in the incidence, types, and outcomes of congenital cardiovascular malformations among children.<sup>27,28</sup>

We found that the incidence of cardiomyopathy was significantly higher in the first year of life than at older ages. Our incidence of 8.34 cases of cardiomyopathy per 100,000 children during the first year of life is very similar to the six-year prevalence of 10 per 100,000 estimated in the Baltimore–Washington Infant Study.<sup>29</sup> The latter study assessed the prevalence of cardiomyopathy, which would be higher than the incidence, but given the narrow age range, this would not have much of an effect. The Baltimore–Washington study also did not exclude secondary cardiomyopathies, which accounted for at least 13 percent of the cases in that study and which were excluded from our data bases. The exclusion of these cases would result in a rate of 8.7 per 100,000, which is quite similar to ours.<sup>29</sup> Postnatal abnormalities of the structure and function of the left ventricle can be related to a less healthy intrauterine milieu,<sup>30</sup> and myocardial injury is frequently found in the perinatal period.<sup>31</sup> Previous studies have suggested that children with dilated cardiomyopathy present in the first two years of life,<sup>20-22,32</sup> with half of the cases seen in the first year.<sup>20</sup>

Although the incidence of cardiomyopathy peaks in the first year of life, a second, smaller peak occurs during adolescence and is related to hypertrophic cardiomyopathy and neuromuscular diseases. The high incidence of hypertrophic cardiomyopathy in the first year of life has not been reported in many previous studies that have focused on older children.<sup>33-36</sup> As a result, several pediatric cardiology textbooks state that clinical manifestations of hypertrophic cardiomyopathy usually do not develop before adolescence and are rarely seen during infancy and childhood.<sup>25,34</sup> Our findings may reflect a change in the practice of family care, with children in affected families being screened earlier. For many children with hypertrophic cardiomyopathy, the young age at diagnosis is due to genetic and meta-

**Table 4. Specific Primary Causes of Hypertrophic and Dilated Cardiomyopathy Diagnosed in 1996, 1997, 1998, and 1999.\***

Cause	Hypertrophic Cardiomyopathy (N=61)†	Dilated Cardiomyopathy (N=77)
	no. of patients (%)	
Inborn error of metabolism	16	5
Disorder of glycogen metabolism	5 (31)	1 (20)
Disorder of mucopolysaccharide metabolism	4 (25)	2 (40)
Disorder of oxidative phosphorylation	5 (31)	2 (40)
Disorder of fatty-acid metabolism	2 (12)	0
Malformation syndrome associated with cardiomyopathy	13	3
Autosomal dominant‡	12 (92)	0
Autosomal recessive	0	2 (67)
Chromosomal defect	1 (8)	1 (33)
Neuromuscular disorder associated with cardiomyopathy	10	30
Muscular dystrophies§	1 (10)	30 (100)
Congenital myopathy	0	0
Ataxia¶	9 (90)	0
Myocarditis	0	21
Confirmed by Dallas criteria on biopsy	0	9 (43)
Probable	0	12 (57)
Familial isolated cardiomyopathy	21	15
Autosomal dominant	19 (90)	12 (80)
X-linked	0	1 (7)
Autosomal recessive	2 (10)	2 (13)
Data missing or Unspecified	1	3

\* Five children with an “other” or unknown type of cardiomyopathy but a known cause are not included. Because of rounding, percentages may not total 100.

† Five of the 61 cases of hypertrophic cardiomyopathy with a known cause were the mixed type (including dilated or restrictive properties).

‡ There were 11 cases of Noonan’s syndrome and 1 case of the Beckwith–Wiedemann syndrome.

§ There were 29 cases of Duchenne’s muscular dystrophy and 2 cases of Becker’s muscular dystrophy.

¶ There were nine cases of Friedreich’s ataxia.

bolic disorders that have not been adequately addressed or recognized in the past.<sup>2,37,38</sup> Our data support the assumption that dilated cardiomyopathy develops more commonly in younger children than in older children.

In 1993, the Pediatric Cardiomyopathy Registry surveyed pediatric cardiology centers in North America for cases of cardiomyopathy.<sup>1</sup> The results showed an estimated incidence of pediatric cardiomyopathy that was nearly 10 times the rate reported in our prospective study. Moreover, the survey suggested that the incidence of cardiomyopathy was constant across pediatric age ranges, whereas we found that the incidence was nearly 12 times as

high before one year of age as it was at or after this age. These data indicate that expert clinical impressions are not an adequate substitute for a prospective incidence study.

The results of the independently conducted Australian study of pediatric cardiomyopathy support our findings.<sup>10</sup> The fact that the findings are similar in geographically distinct regions suggests that genetic factors are important contributors to the development of pediatric cardiomyopathy.

Our study is, by design, limited to cases of pediatric cardiomyopathy evaluated by pediatric cardiologists. Occult disease was not included. In addition, it is possible and indeed probable that some eligible children were not included in our registry. Because various mechanisms could have led to an

undercount, we tried, through our survey of adult cardiologists and our review of ICD-9 codes and echocardiographic findings, to ascertain the extent of the problem and found no new cases. Nonetheless, the number of missed cases may be biased relative to region or age, and such a bias may have contributed to the significant differences in the incidence of cardiomyopathy that we found.

In summary, we prospectively estimated that the incidence of pediatric cardiomyopathy was 1.13 cases per 100,000 children. Most cases are identified at an early age, and the incidence appears to vary according to region, sex, and racial or ethnic origin.

Supported in part by grants (HL53392, CA68484, CA79060, and CA55576) from the National Institutes of Health; the David B. Perini, Jr., Quality of Life Program; the Parker Family Foundation; and the Glover-Crask Trust.

#### APPENDIX

The following persons and institutions were involved in the Pediatric Cardiomyopathy Registry Prospective Study (asterisks denote principal investigators): University of Rochester (Administrative Coordinating Center) — S. Lipshultz,\* M. Grenier, A. Giantris, L. Rossetti, R. Rossetti, K. McCoy, M. Meloche, W. Sullivan, E. Muto, K. Lewis, R. O'Brien, M. Gurell, C. Cianfrini, M. Keesler, M. McDonald, C. Hughes, E. Cadregari, K. McLaughlin; New England Research Institutes (Data Coordinating Center) — L. Sleeper,\* S. McKinlay, L. Cafferata, K. Noonan, A. Lowe, R. Orfaly, L. Gilroy, F. Tighe, P. Nash, N. Pophali, L. Schiavoni, S. Osganian, L. Cuniberti, T. McKee, E. Rauch; Boston Children's Hospital — S. Colan,\* G. Cox, J. Messere, C. Messere, C. Barber, A. Boller; Brigham and Women's Hospital — E.J. Orav; Baylor College of Medicine, Texas Children's Hospital — J. Towbin,\* D. Cline, S. Clunie; Albany Medical College — P. Lurie; Scientific Advisory Council (May 1996–May 2001) — L. Benson, S. Kaplan, T. Klitzner, J. Krischer, W. Lewis, A. Strauss (Chair), G. Pearson, C. Weinstein; Observational Study Monitoring Board (May 2001–present) — H. Gutgesell, J. Krischer (Chair), C. Morris, J. Norman, G. Van Hare, G. Pearson (ex officio); Participating Clinical Centers in the Central Southwest Region — Arkansas, Arkansas Children's Hospital, Little Rock: E. Frazier, R. Morrow, P. Seib; Oklahoma, University Hospital, Oklahoma City: K. Ward, S. Baker; Texas, Cook Children's Heart Center, Pediatric Cardiology Associates, Fort Worth: L. Roten, J.H. Allender, D. Miga, S. Lai, K. Hart; South Texas Pediatric Cardiology Associates, Driscoll Children's Hospital, Corpus Christi: J. Simpson, J. Pastorek, M. Grenier; Children's Heart Center of West Texas, Lubbock: C. Sang, A. Colon; Presbyterian Professional Building III, Dallas: E. Newfeld, T. Carlson, D. Wright, S. Clapp; Texas Tech University, El Paso: J. Schuster, S. Moeller; Pediapep, Heart Center for Children, Dallas: L.A. Pearse, P. Callahan, J. Kao; Healthcare Professional Associates, Amarillo: J. Garcia, P. McLemore; Pediatric Cardiology Associates, San Antonio: K. Bloom, J. Schroeder, T. Hospers, C. Coppedge, J. Brown; University of Texas Medical Branch at Galveston, Children's Hospital, Galveston: W. Pearl; Children's Heart Network, San Antonio: J. Rogers, M. Gaenzel; Children's Cardiology Associates, Austin: S. Rowe, D. Rios, S. Dymond; Baylor College of Medicine, Texas Children's Hospital, Houston: J. Towbin, S. Clunie; University of Texas Health Science Center, Pediatric Cardiology, Houston: S. Wolfe, M. Thaper, T. Williams; University of Texas, Southwestern Medical Center of Dallas, Children's Medical Center, Dallas: M. Lemler, H. Carron, D. Fixler; Wilford Hall Medical Center, Lackland Air Force Base: J. Brownlee, K. Shafer, W. Marek; Participating Clinical Centers in the New England Region — Connecticut, Pediatric Cardiology Associates, Yale University, Pediatric Cardiology, New Haven: P. Bowers, W. Hellenbrand; Pediatric Cardiology Associates, Connecticut Children's Medical Center, Hartford: H. Leopold, L. Chameides; Maine, Eastern Maine Medical Center, Bangor: A. Gilladoga, K. Mazerolle; Pediatric Cardiology Associates, Maine Medical Center, Portland: M. Hourihan; Massachusetts, Floating Hospital for Children, Tufts University School of Medicine, Boston: G. Marx, J. Rhodes, Z. Hijazi, S. Hill; Children's Hospital, Harvard Medical School, Boston: J. Messere, S. Colan, G. Cox; Massachusetts General Hospital, Harvard Medical School, Boston: M. King, B. Ticho; University of Massachusetts Medical School, Worcester: P. Pollack, N. Hagberg; New Hampshire, Regional Program in Pediatric Cardiology, Dartmouth–Hitchcock Medical Center, Lebanon: N. Drucker, M. Flanagan, S. Weindling, N. Berman; Hitchcock Clinic, Manchester Division, Dartmouth–Hitchcock Medical Center, Elliot Hospital, Manchester: S. Rockenmacher; Rhode Island, Hasbro Children's Hospital, Providence: R. Corwin; Pediatric Cardiologist, Providence: P. Rompf, K. Strickland; Rhode Island Hospital, Brown University School of Medicine, Providence: J. Werner; Vermont, Fletcher Allen Health Care, University of Vermont, Burlington: N. Drucker, S. Yeager.

#### REFERENCES

- Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. *Prog Pediatr Cardiol* 2000;12:1-28.
- Schwartz ML, Cox GF, Lin AE, et al. Clinical approach to genetic cardiomyopathy in children. *Circulation* 1996;94:2021-38.
- Kumar K, Thatai D, Saxena A, et al. Pediatric dilated cardiomyopathy: prognosis in a developing nation is comparable to developed nations. *Int J Cardiol* (in press).
- Bilgic A, Ozbarlas N, Ozkutu S, Ozer S, Ozme S. Cardiomyopathies in children: clinical, epidemiological and prognostic evaluation. *Jpn Heart J* 1990;31:789-97.
- Evans RW. Economic and social costs of heart transplantation. *Heart Transplant* 1982;1:243-51.
- Gillum RF. Idiopathic cardiomyopathy in the United States, 1970-1982. *Am Heart J* 1986;111:752-5.
- Boucek MM, Faro A, Novick RJ, Bennett LE, Keck BM, Hosenpud JD. The Registry of the International Society of Heart and Lung Transplantation: Fourth Official Pediatric Report — 2000. *J Heart Lung Transplant* 2001;20:39-52.
- Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. *Am J Epidemiol* 1997;146:385-93.
- Arola A, Touminen J, Ruuskanen O, Jokinen E. Idiopathic dilated cardiomyopathy

- in children: prognostic indicators and outcome. *Pediatrics* 1998;101:369-76.
10. Nugent AW, Daubeney PEF, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. *N Engl J Med* 2003;348:1639-46.
  11. Grenier MA, Osganian SK, Cox GF, et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. *Am Heart J* 2000;139:S86-S95.
  12. Colan SD, Parness IA, Spevak DJ, Sanders SP. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. *J Am Coll Cardiol* 1992;19:619-29.
  13. Estimates of the population of states by age, sex, race and Hispanic origin: 1990 to 1999. Washington, D.C.: Census Bureau, 1999. (Accessed April 1, 2003, at [http://eire.census.gov/popest/archives/state/st\\_sasrh.php](http://eire.census.gov/popest/archives/state/st_sasrh.php).)
  14. Cox GF, Sleeper LA, Lowe AM, et al. Variables associated with a known etiology of cardiomyopathy in children: a retrospective analysis of the Pediatric Cardiomyopathy Registry (PCMR) from 1990-1995. *Circulation* 2001;104:Suppl II:II-588. abstract.
  15. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). *Am J Cardiol* 1992;69:1458-66.
  16. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *N Engl J Med* 1995;332:1738-43.
  17. Tsirka AE, Trinkaus K, Chen S-C, Lipshultz SE, Exil V, Strauss A. The "unnatural" history of pediatric dilated cardiomyopathy. *Circulation* 2000;102:Suppl II:II-406. abstract.
  18. Chang RK, Chen AY, Klitzner TS. Female sex as a risk factor for in-hospital mortality among children undergoing cardiac surgery. *Circulation* 2002;106:1514-22.
  19. Stein H, Shnier MH, Wayburne S, Isaacson C. Cardiomyopathy in African children. *Arch Dis Child* 1964;39:610-7.
  20. Greenwood RD, Nadas AS, Fyler DC. The clinical course of primary myocardial disease in infants and children. *Am Heart J* 1976;92:549-60.
  21. Pongpanich B, Isaraprasart S. Congestive cardiomyopathy in infants and children: clinical features and natural history. *Jpn Heart J* 1985;27:11-5.
  22. Taliercio CP, Seward JB, Driscoll DJ, Fisher LD, Gersh BJ, Tajik AJ. Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history. *J Am Coll Cardiol* 1985;6:1126-31.
  23. Griffin ML, Hernandez A, Martin TC, et al. Dilated cardiomyopathy in infants and children. *J Am Coll Cardiol* 1988;11:139-44.
  24. Chen SC, Nouri S, Balfour I, Jureidini S, Appleton RS. Clinical profile of congestive cardiomyopathy in children. *J Am Coll Cardiol* 1990;15:189-93.
  25. Carvalho JS. Cardiomyopathies. In: Anderson RH, Baker EJ, Macartney FJ, Rigby ML, Shinebourne EA, Tynan M, eds. *Paediatric cardiology*. 2nd ed. London: Churchill Livingstone, 2002:1595-643.
  26. Coughlin SS, Comstock GW, Baughman KL. Descriptive epidemiology of idiopathic dilated cardiomyopathy in Washington County, Maryland, 1975-1991. *J Clin Epidemiol* 1993;46:1003-8.
  27. Correa-Villasenor A, McCarter R, Downing J, Ferencz C. White-black differences in cardiovascular malformations in infancy and socioeconomic factors. *Am J Epidemiol* 1991;134:393-402.
  28. Boneva RS, Botto LD, Moore CA, Yang Q, Correa A, Erickson JD. Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979-1997. *Circulation* 2001;103:2376-81.
  29. Ferencz C, Neill CA. Cardiomyopathy in infancy: observations in an epidemiologic study. *Pediatr Cardiol* 1992;13:65-71.
  30. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiovascular status of infants and children of women infected with HIV-1 (P<sup>2</sup>C<sup>2</sup> HIV): a cohort study. *Lancet* 2002;360:368-73.
  31. Simbre VC, Sinkin RA, Hart S, et al. Un-suspected myocardial injury in otherwise healthy newborns. *Pediatr Res* 2002;51: Suppl:37A. abstract.
  32. Schmaltz A, Apitz J, Hort W. Dilated cardiomyopathy in childhood: problems of diagnosis and long-term follow-up. *Eur Heart J* 1987;8:100-5.
  33. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology and therapy. *N Engl J Med* 1987;316:780-9, 844-52.
  34. Maron BJ. Hypertrophic cardiomyopathy. In: Allen HD, Clark EB, Gutgesell HP, Driscoll DJ, eds. *Moss and Adams' heart disease in infants, children, and adolescents: including the fetus and young adult*. 6th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:1167-86.
  35. Maron BJ, Roberts WC. Cardiomyopathies in the first two decades of life. In: Engle MA, ed. *Pediatric cardiovascular disease*. Vol. 11 of *Cardiovascular clinics*. Philadelphia: F.A. Davis, 1981:35-78.
  36. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. *Circulation* 1995;92:2488-95.
  37. Towbin JA, Lipshultz SE. Genetics of neonatal cardiomyopathy. *Curr Opin Cardiol* 1999;14:250-62.
  38. Towbin JA. Cardiomyopathies. In: Moller JH, Hoffman JIE, eds. *Pediatric cardiovascular medicine*. New York: Churchill Livingstone, 2000:753-67.